To evaluate the percentage of subjects that reach the diabetic hypertensive blood pressure goal of <130/80 with amlodipine versus placebo in subjects initially treated with quinapril or losartan.

Condition	Intervention	Phase
Hypertension	Drug: Amlodipine	Phase IV

Further Study Details: 

Primary Outcomes: The percentage of subjects that reach the JNC diabetic hypertensive BP goal of <130/80 will be assessed at Week 0 (Visit 2-Randomization), Week 5 (Visit 3), Week 9 (Visit 4), Week 15 (Visit 5) and Week 20 (Visit 6 - Final Evaluation).
Secondary Outcomes: Percentage of subjects reaching SBP goal of <130 mmHg and reaching DBP goal of <80mmHg; change from baseline blood pressures (SBP and DBP); percentage of subjects with SBP >160mmHg and/or DBP >100mmHg at timepoints Visit 2, Visit 3, Visit 4, Visit 5, and
Expected Total Enrollment:  700

Ages Eligible for Study:  30 Years   -   75 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Documented evidence of Type 2 diabetes as defined by the ADA guidelines and documented evidence of Hypertension (various SBP/DBP ranges).

Exclusion Criteria:

• A previous history or intolerance or hypersensitivity to calcium channel blockers, ARBs or ACE inhibitors.

Study chairs or principal investigators

Pfizer CT.gov Call Center,  Study Director,  Pfizer   

Study ID Numbers:  A0531063
Last Updated:  September 11, 2005
Record first received:  September 8, 2005
ClinicalTrials.gov Identifier:  NCT00159692
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13